The US launch of Mitsubishi Tanabe Pharma Corp.'s Radicava (edaravone) for amyotrophic lateral sclerosis (ALS) is a key step to realizing the company’s sales ambitions in a market where its presence so far has been limited.
Radicava is being marketed (at a cost of around $145,000 for a year's therapy) by the company's wholly owned US...







